☰

Hisham H. Qosa, Ph.D. - Publications

Affiliations: 
2014 University Of Louisiana at Monroe 
Area:
Pharmacy, Pharmacology, Neuroscience Biology
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

16/28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Volpe DA, Qosa H. Challenges with the precise prediction of ABC-transporter interactions for improved drug discovery. Expert Opinion On Drug Discovery. 13: 697-707. PMID 29943645 DOI: 10.1080/17460441.2018.1493454  0.354
2016 Qosa H, Kaddoumi A. Effect of mouse strain as a background for Alzheimer's disease models on the clearance of amyloid-β. Journal of Systems and Integrative Neuroscience. 2: 135-140. PMID 27478623 DOI: 10.15761/JSIN.1000123  0.655
2016 Qosa H, Mohamed LA, Alqahtani S, Abuasal BS, Hill RA, Kaddoumi A. Transporters as Drug Targets in Neurological Diseases. Clinical Pharmacology and Therapeutics. PMID 27447939 DOI: 10.1002/Cpt.435  0.597
2016 Qosa H, Mohamed LA, Al Rihani SB, Batarseh YS, Duong QV, Keller JN, Kaddoumi A. High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity. Journal of Alzheimer's Disease : Jad. PMID 27392852 DOI: 10.3233/Jad-151179  0.665
2016 Qosa H, Lichter J, Sarlo M, Markandaiah SS, McAvoy K, Richard JP, Jablonski MR, Maragakis NJ, Pasinelli P, Trotti D. Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-Glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis. Glia. PMID 27158936 DOI: 10.1002/Glia.23003  0.395
2015 Qosa H, Batarseh YS, Mohyeldin MM, El Sayed KA, Keller JN, Kaddoumi A. Oleocanthal Enhances Amyloid-β Clearance from the Brains of TgSwDI Mice and in Vitro across a Human Blood-Brain Barrier Model. Acs Chemical Neuroscience. PMID 26348065 DOI: 10.1021/Acschemneuro.5B00190  0.71
2015 Qosa H, Mohamed LA, Batarseh YS, Alqahtani S, Ibrahim B, LeVine H, Keller JN, Kaddoumi A. Extra-virgin olive oil attenuates amyloid-β and tau pathologies in the brains of TgSwDI mice. The Journal of Nutritional Biochemistry. PMID 26344778 DOI: 10.1016/J.Jnutbio.2015.07.022  0.689
2015 Qosa H, Miller DS, Pasinelli P, Trotti D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Research. PMID 26187753 DOI: 10.1016/J.Brainres.2015.07.005  0.433
2015 Alqahtani S, Qosa H, Primeaux B, Kaddoumi A. Orlistat limits cholesterol intestinal absorption by Niemann-pick C1-like 1 (NPC1L1) inhibition. European Journal of Pharmacology. 762: 263-9. PMID 26048312 DOI: 10.1016/J.Ejphar.2015.05.060  0.572
2015 Mohamed LA, Qosa H, Kaddoumi A. Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats. Acs Chemical Neuroscience. 6: 725-36. PMID 25782004 DOI: 10.1021/Acschemneuro.5B00040  0.709
2014 Qosa H, LeVine H, Keller JN, Kaddoumi A. Mixed oligomers and monomeric amyloid-β disrupts endothelial cells integrity and reduces monomeric amyloid-β transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. Biochimica Et Biophysica Acta. 1842: 1806-15. PMID 24997450 DOI: 10.1016/J.Bbadis.2014.06.029  0.696
2014 Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud PO, Keller JN, Kaddoumi A. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology. 79: 668-78. PMID 24467845 DOI: 10.1016/J.Neuropharm.2014.01.023  0.707
2013 Abuznait AH, Qosa H, Busnena BA, El Sayed KA, Kaddoumi A. Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies. Acs Chemical Neuroscience. 4: 973-82. PMID 23414128 DOI: 10.1021/Cn400024Q  0.716
2012 Abuasal BS, Qosa H, Sylvester PW, Kaddoumi A. Comparison of the intestinal absorption and bioavailability of γ-tocotrienol and α-tocopherol: in vitro, in situ and in vivo studies. Biopharmaceutics & Drug Disposition. 33: 246-56. PMID 22528033 DOI: 10.1002/Bdd.1790  0.564
2012 Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 31: 151-65. PMID 22504320 DOI: 10.3233/Jad-2012-120319  0.709
2011 Abuznait AH, Qosa H, O'Connell ND, Akbarian-Tefaghi J, Sylvester PW, El Sayed KA, Kaddoumi A. Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products. Food and Chemical Toxicology : An International Journal Published For the British Industrial Biological Research Association. 49: 2765-72. PMID 21851848 DOI: 10.1016/J.Fct.2011.08.004  0.574
Low-probability matches (unlikely to be authored by this person)
2018 Qosa H, Avaritt BR, Hartman NR, Volpe DA. In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia. Cancer Chemotherapy and Pharmacology. PMID 30105461 DOI: 10.1007/S00280-018-3665-X  0.277
2018 Qosa H, Volpe DA. The development of biological therapies for neurological diseases: moving on from previous failures. Expert Opinion On Drug Discovery. 13: 283-293. PMID 29394876 DOI: 10.1080/17460441.2018.1437142  0.245
2022 Younis IR, Manchandani P, Hassan HE, Qosa H. Trends in FDA Transporter-Based Post-Marketing Requirements and Commitments Over the Last Decade. Clinical Pharmacology and Therapeutics. PMID 35780478 DOI: 10.1002/cpt.2701  0.227
2021 Qosa H, Ribeiro AJS, Hartman NR, Volpe DA. Characterization of a commercially available line of iPSC hepatocytes as models of hepatocyte function and toxicity for regulatory purposes. Journal of Pharmacological and Toxicological Methods. 110: 107083. PMID 34098110 DOI: 10.1016/j.vascn.2021.107083  0.205
2015 Al-Diab O, Yousef A, Manassrah EA, Masadeh A, Olemat M, Qosa H, Kherbash A, Bulatova N. Genotype and Haplotype Analysis of ABCB1 at 1236, 2677 and 3435 among Jordanian Population Tropical Journal of Pharmaceutical Research. 14: 1013-1019. DOI: 10.4314/Tjpr.V14I6.11  0.202
2011 Bulatova N, Yousef AM, Al-Khayyat G, Qosa H. Adverse effects of tacrolimus in renal transplant patients from living donors. Current Drug Safety. 6: 3-11. PMID 21241247 DOI: 10.2174/157488611794480043  0.195
2022 Qosa H, Hassan HE, Younis IR. Overview of Clinical Pharmacology Packages of New Drug Applications Approved for the Treatment of Rare Diseases. Journal of Clinical Pharmacology. S72-S78. PMID 36461747 DOI: 10.1002/jcph.2167  0.194
2022 Ravenstijn P, Chetty M, Manchandani P, Elmeliegy M, Qosa H, Younis I. Design and conduct considerations for studies in patients with hepatic impairment. Clinical and Translational Science. PMID 36176049 DOI: 10.1111/cts.13428  0.133
2021 Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, Qosa H, Liu J, Zhao H, Biable M, Hotaki LT, Shen YL, Pazdur R, Beaver JA, Singh H, et al. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34462287 DOI: 10.1158/1078-0432.CCR-21-1466  0.113
2023 Qosa H, de Oliveira CHMC, Cizza G, Lawitz EJ, Colletti N, Wetherington J, Charles ED, Tirucherai GS. Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment. Clinical and Translational Science. PMID 37654022 DOI: 10.1111/cts.13581  0.102
2021 Pulte ED, Norsworthy KJ, Wang Y, Xu Q, Qosa H, Gudi R, Przepiorka D, Fu W, Okusanya OO, Goldberg KB, de Claro RA, Farrell AT, Pazdur R. FDA Approval Summary: Gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33632926 DOI: 10.1158/1078-0432.CCR-20-4271  0.076
2016 Yousef AM, Qosa H, Bulatova N, Abuhaliema A, Almadhoun H, Khayyat G, Olemat M. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients. Iranian Journal of Kidney Diseases. 10: 156-63. PMID 27225724  0.045
Hide low-probability matches.